Is Wegovy a Dual Agonist, or Does It Work on a Single Receptor?

What does 'GLP-1 receptor agonist' actually mean for Wegovy?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It tells your pancreas to release insulin, signals the brain that you're satisfied, and slows the rate at which food moves out of your stomach. Semaglutide (the active ingredient in Wegovy) is a synthetic molecule engineered to bind to and activate GLP-1 receptors in the same way, but far more persistently than the hormone your body produces naturally. The result is a sustained reduction in appetite and, over time, meaningful weight loss in people who also make dietary and activity changes.

A question our prescribers hear most weeks is whether Wegovy and Mounjaro are essentially the same drug given the similarity in how they're described. They're not. Wegovy works on one receptor type. That single-target action is well-understood, backed by large clinical-trial programmes, and has a well-characterised side-effect profile. You can read a thorough breakdown of how semaglutide functions as a GLP-1 medicine on our overview of Wegovy as a GLP-1 agonist, which covers the mechanism in more detail. The NHS semaglutide medicines page is also a reliable patient-level reference.

What makes tirzepatide a dual agonist where semaglutide is not?

Tirzepatide adds a second receptor into the picture: GIP, or glucose-dependent insulinotropic polypeptide. GIP is another gut hormone, released earlier in the digestive process than GLP-1, and it influences how fat tissue handles energy as well as contributing its own appetite signals. By activating both receptors, tirzepatide creates a compound effect that clinical trials suggest produces greater average weight loss than semaglutide at standard doses.

In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, participants taking tirzepatide lost more body weight on average than those taking semaglutide 2.4mg over 72 weeks, a direct head-to-head comparison in adults with obesity and no diabetes. That does not make tirzepatide automatically the right choice; tolerability, personal medical history, contraindications and cost all feed into the decision. Our page on semaglutide as a receptor agonist explores the science further if you want the detail before a conversation with a prescriber.

It is worth being precise about terminology here: some sources use 'dual agonist' loosely. For clinical purposes in the UK, only tirzepatide holds a licence as a dual GIP and GLP-1 receptor agonist for weight management. Wegovy does not.

Does Wegovy's single-agonist mechanism limit how much weight it can help someone lose?

In clinical trials, semaglutide 2.4mg produced an average body-weight reduction of around 15% over 68 weeks in the STEP 1 study (a large, placebo-controlled trial in adults with obesity) as reported in the published STEP 1 paper in the NEJM. The newer 7.2mg maintenance dose, approved by the MHRA in early 2026, showed approximately 20.7% average weight loss in trials, which narrows the gap with tirzepatide considerably. So while Wegovy targets one receptor rather than two, the magnitude of effect at higher doses is substantial.

Individual response varies. Factors including starting weight, diet adherence, activity levels and how well a person tolerates dose increases all shape real-world outcomes. The most useful comparison is not a headline percentage, it is how a given medicine fits an individual's medical picture. If you are exploring whether Wegovy is right for you, our Wegovy treatment page sets out eligibility, the dosing schedule and what to expect, and you can explore the full range of weight-loss treatment options we offer for broader context. Cost is a factor for many people; our page on Wegovy pricing in the UK gives an honest breakdown of what private treatment typically involves.

Which medicine is right for you, and how is that decision made?

Neither mechanism is universally superior. Wegovy's GLP-1 receptor agonism is well-established, has been in clinical use for longer, and suits many people extremely well. Tirzepatide's dual action produces higher average losses in trial populations but brings its own tolerability profile and contraindication considerations. Prescribers weigh both options against a patient's full medical history, other medications, BMI, and weight-related conditions, and if you are wondering when Wegovy is coming to the UK in its newer formulations, our dedicated page covers the latest availability updates.

At nume, every consultation is personally read by a GPhC-registered Independent Prescriber on the same day, not processed by software. They consider the clinical picture in full before recommending any medicine, including confirming details such as whether semaglutide is a GLP-1 agonist and what that means practically for your treatment. If you have questions before starting a consultation, our FAQs cover the most common queries. These are prescription-only medicines; the mechanism question is genuinely interesting, but suitability is always the first question a prescriber answers.